A 35-year-old man with a 10-year history of focal seizures (temporal lobe epilepsy) presents with recurrent breakthrough seizures despite adequate dosing of carbamazepine. Serum carbamazepine level is 8 µg/mL (therapeutic range 4–12 µg/mL). He has been compliant with medication. He is also on rifampicin for tuberculosis (recently started 3 months ago). What is the most likely explanation for his loss of seizure control?

Explanation

## Clinical Context A patient with previously well-controlled temporal lobe epilepsy on carbamazepine develops breakthrough seizures after starting rifampicin for tuberculosis. Despite an adequate serum carbamazepine level (8 µg/mL, within therapeutic range), seizure control is lost—suggesting a pharmacokinetic interaction rather than inadequate dosing or drug resistance. ## Drug Interaction: Rifampicin and Carbamazepine **Key Point:** Rifampicin is a potent inducer of hepatic cytochrome P450 enzymes, particularly CYP3A4, CYP2C9, and CYP2C19. Carbamazepine is metabolized primarily by CYP3A4. **High-Yield:** When rifampicin is added to carbamazepine, CYP3A4 induction accelerates carbamazepine metabolism, increasing clearance and reducing serum concentrations. This occurs *despite* the serum level appearing "therapeutic"—the patient may require a higher dose to maintain efficacy. **Clinical Pearl:** The timing is critical: the patient started rifampicin 3 months ago, and breakthrough seizures developed afterward. This temporal relationship is classic for enzyme induction. ## Mechanism of Rifampicin-Induced Carbamazepine Metabolism ```mermaid flowchart TD A[Rifampicin added to therapy]:::action --> B[Binds to PXR/CAR in hepatocytes]:::outcome B --> C[Upregulates CYP3A4, CYP2C9, CYP2C19 expression]:::outcome C --> D[Carbamazepine metabolism accelerated]:::action D --> E[Serum carbamazepine concentration ↓]:::outcome E --> F[Subtherapeutic drug effect despite 'normal' level']:::urgent F --> G[Breakthrough seizures]:::urgent ``` ## Why the Serum Level Appears "Normal" The therapeutic range for carbamazepine (4–12 µg/mL) was established in patients *not* receiving enzyme inducers. In the presence of rifampicin, a patient may need a *higher* serum level to achieve the same clinical effect because the drug is being cleared faster. A level of 8 µg/mL may be subtherapeutic in this context. ## Management Approach **Key Point:** The carbamazepine dose should be increased by 25–50% when rifampicin is co-administered, with therapeutic drug monitoring to guide dosing. | Step | Action | |------|--------| | 1 | Recognize the drug interaction (temporal relationship + adequate compliance) | | 2 | Increase carbamazepine dose by 25–50% | | 3 | Recheck serum carbamazepine level in 1–2 weeks | | 4 | Titrate to seizure control (may require levels >12 µg/mL) | | 5 | Plan dose reduction when rifampicin course ends (TB treatment typically 6 months) | ## Other CYP3A4-Inducing Drugs That Interact with Carbamazepine - Phenytoin, phenobarbital (other antiepileptics) - St. John's Wort - Glucocorticoids (high-dose) - Oral contraceptives (also reduced efficacy) **Warning:** Rifampicin also induces carbamazepine's own metabolism—a phenomenon called "autoinduction." However, autoinduction occurs over weeks to months after starting carbamazepine itself, not after adding a second drug. In this case, the temporal relationship (starting rifampicin 3 months ago) and the presence of a known enzyme inducer make rifampicin the culprit. [cite:KD Tripathi 8e Ch 12; Harrison 21e Ch 369]